Longevity Peptides: Bioregulators, Mitochondrial Peptides and the State of the Science

Longevity peptides are short amino acid sequences being studied for their potential to slow, modify, or reverse specific biological processes that drive aging. Unlike conventional pharmaceuticals that treat disease symptoms, these compounds target the upstream mechanisms that make aging-related disease more likely in the first place – an approach sometimes called “geroprotection.”

The field is genuinely young. The first mitochondrial-derived peptide (humanin) was identified in 2001. MOTS-c was discovered in 2015. FOXO4-DRI’s senolytic mechanism was published in 2017. Khavinson’s bioregulator work stretches back further (1970s), but remained almost entirely within Russian-language literature until the 2000s. What connects these compounds is not a shared mechanism – they target different aging hallmarks through different pathways – but a shared proposition: that short peptide sequences can modulate fundamental aging biology.

This hub provides a map of the longevity peptide landscape, organised by which aging hallmark each compound targets. Each spoke article linked below covers that compound in full depth – mechanism, evidence, regulation, safety. This page covers only the cross-class overview and comparison.

The longevity peptides under active research can be grouped by which aging hallmark they primarily target. Most aging hallmarks are interconnected – mitochondrial dysfunction contributes to telomere attrition, cellular senescence drives chronic inflammation, and so on – so these categories overlap. But the primary mechanism of each compound determines where it sits.

1. Telomere Maintenance

Epitalon (AEDG) is the primary telomere-focused peptide. A synthetic tetrapeptide developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it has demonstrated telomerase activation in human fibroblasts and lymphocytes in vitro, extended maximum lifespan by 12-13% in mice, and restored melatonin rhythms in aged primates. The FDA’s PCAC will review it on July 24, 2026, for insomnia. Over 100 papers have been published, though the majority come from Khavinson’s group. No randomised controlled trial in humans exists.

2. Mitochondrial Function

MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA, discovered at USC in 2015. It activates AMPK, mimics some metabolic effects of exercise, has shown bone-protective and anti-obesity effects in animals, and is under PCAC review on July 23, 2026 for obesity and osteoporosis. It is prohibited by WADA under S4.4.1 (AMPK activators). A modified analogue (CB4211) completed Phase 1a/1b clinical testing for NASH/obesity with positive safety and biomarker results.

SS-31 (elamipretide) is the most clinically advanced longevity peptide. It targets cardiolipin in the inner mitochondrial membrane, stabilising the electron transport chain and protecting bioenergetic function. Unlike MOTS-c, SS-31 has reached Phase III clinical trials – most notably in Barth syndrome, a rare mitochondrial cardiomyopathy. It represents the mitochondrial approach that is furthest along the regulatory pathway.

3. Cellular Senescence

FOXO4-DRI is a D-retro-inverso peptide designed to disrupt the interaction between FOXO4 and p53 in senescent cells. By blocking this interaction, FOXO4-DRI triggers selective apoptosis of senescent cells while leaving healthy cells unaffected – a “senolytic” mechanism. Published in Cell in 2017 by Baar et al. at Erasmus MC, the compound restored fur density, renal function, and fitness in naturally aged mice. It remains preclinical, with no clinical trials initiated, but it represents the only peptide-based senolytic in active research.

4. Bioregulation (Khavinson Peptides)

Pinealon is a tripeptide (Glu-Asp-Arg) from the same Khavinson bioregulator programme that produced epitalon. It is hypothesised to interact directly with DNA promoter regions to modulate tissue-specific gene expression, particularly in the brain. Huberman discussed its potential effects on REM sleep architecture. It represents the brain-targeted arm of the bioregulator approach. For a full overview of the Khavinson bioregulator programme and its theoretical framework, see the Khavinson Bioregulators Overview. For the direct comparison between the two Khavinson pineal peptides, see Epitalon vs Pinealon.

5. Immune Senescence

Thymalin and thymulin peptides target immune aging through the thymic axis. The thymus gland involutes (shrinks and loses function) throughout adulthood, which is a major driver of age-related immune decline. Khavinson’s thymic peptides aim to partially reverse this process. Thymalin has been studied in Russia alongside epithalamin in combined longevity protocols. These compounds are covered within the Khavinson Bioregulators Overview linked above.

The following table compares the key longevity peptides across mechanism, evidence quality, and regulatory status. Evidence quality reflects the strongest available tier, not the volume of data.

Compound	Primary Target	Mechanism	Strongest Evidence	FDA Status
Epitalon (AEDG)	Telomere maintenance	Telomerase activation, melatonin synthesis	Animal lifespan + primate melatonin	PCAC Jul 24, 2026 (insomnia)
MOTS-c	Mitochondrial function	AMPK activation, exercise mimetic	Phase 1 (analogue) + top-tier preclinical	PCAC Jul 23, 2026 (obesity / osteoporosis)
SS-31 (elamipretide)	Mitochondrial function	Cardiolipin stabilisation	Phase III (Barth syndrome)	Investigational (NDA pathway)
FOXO4-DRI	Cellular senescence	Senolytic (FOXO4-p53 disruption)	Preclinical (aged mice, Cell 2017)	Not evaluated
Pinealon (EDR)	Bioregulation (brain)	Proposed epigenetic gene regulation	Preclinical (cell culture + animal)	Not evaluated

This is the question most people searching “longevity peptides” are trying to answer, but it is important to be precise about what the evidence actually supports versus what the consumer market claims.

If the research interest is metabolic health, insulin sensitivity, or exercise-related outcomes, MOTS-c has the strongest mechanistic rationale and the most geographically distributed evidence base. If the interest is sleep and circadian function, epitalon’s melatonin-restoration pathway is the most relevant, and the upcoming PCAC insomnia review will be the first formal assessment of that claim. If the interest is mitochondrial bioenergetics and the most advanced clinical pathway, SS-31 is the clear leader with Phase III data. If the interest is the emerging field of senolytics, FOXO4-DRI is the only peptide-based option, though it remains deeply preclinical. If the interest is the Khavinson bioregulator framework as a whole, the Khavinson Bioregulators Overview (linked above) covers the theoretical basis and the full range of tissue-specific peptides.

The bottom line: The longevity peptide field is real science conducted by serious researchers, but it is at an early stage of clinical translation – the gap between promising preclinical signals and proven human therapeutics remains the defining feature of the entire space.

The July 2026 PCAC meetings are the most significant regulatory event for longevity peptides to date. Both epitalon (July 24, for insomnia) and MOTS-c (July 23, for obesity and osteoporosis) will be evaluated for potential inclusion on the Section 503A Bulk Drug Substances List. Both were removed from Category 2 on April 15, 2026, following the Kennedy-era policy shift. A positive PCAC recommendation would begin the rulemaking process that could eventually allow licensed compounding pharmacies to prepare these peptides with individual prescriptions.

SS-31 follows a conventional NDA pathway through Stealth BioTherapeutics, entirely separate from the compounding framework. FOXO4-DRI and pinealon are not under any regulatory evaluation and remain available only through research-chemical suppliers.

For the full regulatory framework, see the Category 1 vs Category 2 guide and the RFK Peptide Reclassification Tracker.

What is the best longevity peptide?

There is no single “best” longevity peptide because each targets a different aging hallmark. SS-31 has the most advanced clinical data (Phase III). MOTS-c has the strongest mechanistic rationale for metabolic aging. Epitalon has the longest research history for telomere biology. The answer depends entirely on which aspect of aging biology is of interest and what level of evidence is considered acceptable.

Are longevity peptides legal?

None of the longevity peptides covered here are approved for human therapeutic use by the FDA, MHRA, or TGA. Most can be purchased from research-chemical suppliers labelled “for research use only.” MOTS-c is specifically prohibited by WADA. The legal position varies by country; see our guides to peptide legality in the US, UK and Australia.

What are Khavinson bioregulators?

Khavinson bioregulators are short peptides (typically 2-4 amino acids) derived from tissue-specific extracts, developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. The framework proposes that these short sequences interact directly with DNA promoter regions to modulate tissue-specific gene expression. Epitalon (pineal-derived) and pinealon (also pineal-derived, brain-targeted) are the best-known examples. The Khavinson Bioregulators Overview (linked above in the bioregulation section) covers the full framework.

What is a senolytic peptide?

A senolytic is any compound that selectively destroys senescent cells – damaged cells that have stopped dividing but remain metabolically active, secreting inflammatory signals that damage surrounding tissue. FOXO4-DRI is the only peptide-based senolytic currently under research. Most other senolytics (dasatinib, quercetin, navitoclax) are small molecules. The FOXO4-DRI guide (linked above in the senescence section) covers the compound in full depth.